Dexcel Company Profile
What is the competitive landscape for DEXCEL
DEXCEL has fifteen approved drugs.
There are seven US patents protecting DEXCEL drugs. There is one tentative approval on DEXCEL drugs.
Summary for Dexcel
| US Patents: | 7 |
| Tradenames: | 13 |
| Ingredients: | 13 |
| NDAs: | 15 |
| Patent Litigation for Dexcel: | See patent lawsuits for Dexcel |
Drugs and US Patents for Dexcel
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dexcel Pharma | OMEPRAZOLE | omeprazole | TABLET, DELAYED RELEASE;ORAL | 022032-001 | Dec 4, 2007 | OTC | Yes | Yes | 12,599,565 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Dexcel | OMEPRAZOLE | omeprazole | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | 209400-001 | Jul 5, 2017 | OTC | Yes | Yes | 10,076,494 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Dexcel | DONEPEZIL HYDROCHLORIDE | donepezil hydrochloride | TABLET;ORAL | 203713-001 | Feb 19, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Dexcel | OMEPRAZOLE | omeprazole | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | 209400-001 | Jul 5, 2017 | OTC | Yes | Yes | 10,835,488 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Dexcel
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Dexcel Pharma | OMEPRAZOLE | omeprazole | TABLET, DELAYED RELEASE;ORAL | 022032-001 | Dec 4, 2007 | 9,023,391 | ⤷ Start Trial |
| Dexcel Pharma | PERIOCHIP | chlorhexidine gluconate | TABLET;DENTAL | 020774-001 | May 15, 1998 | 5,023,082 | ⤷ Start Trial |
| Dexcel Pharma | PERIOCHIP | chlorhexidine gluconate | TABLET;DENTAL | 020774-001 | May 15, 1998 | 5,002,769 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for DEXCEL drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
International Patents for Dexcel Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 208925 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2009136398 | ⤷ Start Trial |
| Australia | 2017285390 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2016174664 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Dexcel Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1411900 | 2011C/016 | Belgium | ⤷ Start Trial | PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214 |
| 1830843 | 2015C/038 | Belgium | ⤷ Start Trial | PRODUCT NAME: NINTEDANIB, OU UN TAUTOMERE DE CELUI-CI, DES MELANGES DE CEUX-CI OU UN SEL DE CELUI-CI, SPECIFIQUEMENTNINTEDANIB SOUS FORME D'ESILATE; AUTHORISATION NUMBER AND DATE: EU/1/14/979/001 20150119 |
| 1666481 | CR 2017 00035 | Denmark | ⤷ Start Trial | PRODUCT NAME: TOFACITINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, HERUNDER CITRAT-SALTET; REG. NO/DATE: EU/1/17/1178/001-003 20170324 |
| 1830843 | 15C0046 | France | ⤷ Start Trial | PRODUCT NAME: NINTEDANIB,SES TAUTOMERES ET LEURS MELANGES AINSI QUE LES SELS PHYSIOLOGIQUEMENT ACCEPTABLES DE NINTEDANIB ET PLUS PARTICULIEREMENT L'ESILATE; REGISTRATION NO/DATE: EU/1/14/979 20150119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
